Asher Biotherapeutics IPO

Asher Biotherapeutics, also known as Asher Bio, is a biotechnology company developing immunotherapies intended for cancer, autoimmune disorders, and infectious diseases. Asher Biotherapeutics was founded in 2019 by Ivana Djuretic and Andy Yeungand and is headquartered in San Francisco, CA. The company is committed to creating new treatment paradigms by using its proprietary cis-targeting platform to engineer therapies that selectively engage immune cells.

Register for Details

For more details on financing and valuation for Asher Biotherapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn More About Asher Biotherapeutics

To invest in Asher Biotherapeutics pre-IPO

Can you invest in Asher Biotherapeutics pre-IPO?

Asher Biotherapeutics is a privately held company and is not publicly traded, therefore investing in Asher Biotherapeutics pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

Can you sell shares of Asher Biotherapeutics before it goes public?

You can seek to sell your shares in Asher Biotherapeutics while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.

What is the pre-IPO value of my Asher Biotherapeutics shares?

To determine the value of your Asher Biotherapeutics shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Asher Biotherapeutics shares. You can also learn more about how to sell your private shares before getting started.

Is Asher Biotherapeutics a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.

To learn more about Asher Biotherapeutics potential IPO

Will Asher Biotherapeutics go IPO?

Asher Biotherapeutics has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.

What is Asher Biotherapeutics’ IPO price?

The Asher Biotherapeutics IPO price does not exist at this time, as Asher Biotherapeutics is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Asher Biotherapeutics register for Forge Markets, today.

When was Asher Biotherapeutics founded?

Asher Biotherapeutics was founded in 2019.

What is Asher Biotherapeutics funding to date?

Asher Biotherapeutics has raised $1.05B to date.

Who are Asher Biotherapeutics’s major investors?

Wellington Management
Y Combinator
Emles Venture Partners
Ra Capital Management
Bristol Myers Squibb
Marshall Wace
Janus Henderson Investors
The Invus Group
Logos Capital
Third Rock Ventures
Boxer Capital
Alexandria Venture Investments
GoAhead Ventures
AstraZeneca
Mission BioCapital
MBC BioLabs

Asher Biotherapeutics Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/16/2024 Series C $55MM $xx.xx $428.78MM Astrazeneca, Boxer Capital, Bristol Myers Squibb, Janus Henderson Investors, Ra Capital, Third Rock Ventures, Wellington Management
Price per Share
$xx.xx
Shares Outstanding
47,313,447
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Astrazeneca, Boxer Capital, Bristol Myers Squibb, Janus Henderson Investors, Ra Capital, Third Rock Ventures, Wellington Management
09/01/2021 Series B $108MM $xx.xx $281.98MM Alexandria Venture Investments, Boxer Capital, Invus, Janus Henderson Investors, Logos Capital, Marshall Wace, Mission Biocapital, Ra Capital Management, Third Rock Ventures, Wellington Management Company
Price per Share
$xx.xx
Shares Outstanding
53,771,459
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.7x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Alexandria Venture Investments, Boxer Capital, Invus, Janus Henderson Investors, Logos Capital, Marshall Wace, Mission Biocapital, Ra Capital Management, Third Rock Ventures, Wellington Management Company
03/23/2021 Series A $55MM $xx.xx $79.5MM Boxer Capital, Invus, Mbc Biolabs, Third Rock Ventures, Y Combinator
Price per Share
$xx.xx
Shares Outstanding
55,000,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Boxer Capital, Invus, Mbc Biolabs, Third Rock Ventures, Y Combinator
08/19/2019 Series Seed-1 $150,003.00 $xx.xx $7.7MM Y Combinator
Price per Share
$xx.xx
Shares Outstanding
1,050,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
08/19/2019 Series Seed-2 $290,000.00 $xx.xx $7.7MM Y Combinator
Price per Share
$xx.xx
Shares Outstanding
362,500
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
08/19/2019 Series Seed-3 $3.21MM $xx.xx $7.7MM Y Combinator
Price per Share
$xx.xx
Shares Outstanding
3,210,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Y Combinator
Updated on: Dec 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.